CONDITION

Epilepsy in Dogs

A neurological condition characterised by recurrent seizures, where diagnosis and management depend on tracking patterns over time.

Why this matters now

Epilepsy in dogs can emerge at virtually any age, though idiopathic epilepsy — the most common form — tends to present between one and five years of age. Certain breeds, including Border Collies, Labrador Retrievers, German Shepherds, Belgian Tervurens, and Beagles, appear to carry a higher genetic predisposition, suggesting heritable factors in many cases. Structural epilepsy, arising from identifiable brain lesions such as tumours, inflammatory disease, or vascular events, may present outside this typical age window and can appear in older dogs with no prior seizure history. Reactive seizures triggered by metabolic disturbances — hepatic encephalopathy, hypoglycaemia, or toxin exposure — can occur at any life stage and often resolve when the underlying cause is addressed. The age of onset, breed background, and pattern of seizure activity all contribute to how veterinary professionals categorise and investigate the condition.

The trajectory of epilepsy varies considerably between individuals, and predicting how any single dog's seizure pattern will evolve remains challenging. Some dogs experience infrequent, isolated seizures that remain stable over years, while others may show a pattern of increasing frequency or severity over time — a phenomenon sometimes described as seizure kindling. Cluster seizures, where multiple events occur within a 24-hour period, and status epilepticus, where seizure activity becomes prolonged or continuous, represent more concerning patterns that may emerge unpredictably. The response to anti-seizure medications also varies widely; some dogs achieve excellent seizure control with a single medication, while others may require combinations of therapies with only partial reduction in seizure frequency. Long-term management often involves ongoing adjustments as the condition evolves, and what works well initially may need modification over months or years.

Signals & patterns

Early signals

Focal seizure activity

Early seizure presentations may appear subtle and easy to misinterpret. A dog might display repetitive twitching of one side of the face, rhythmic jaw movements sometimes described as 'fly-biting', or brief episodes of staring and unresponsiveness. These focal signs can precede generalised seizures or occur independently, and owners may initially attribute them to quirky behaviour rather than neurological events.

Post-ictal disorientation

Following a seizure, dogs typically enter a post-ictal phase characterised by confusion, restlessness, temporary blindness, or excessive drinking and eating. This recovery period can last from minutes to several hours and may be the first noticeable abnormality if the seizure itself occurred unwitnessed. The severity and duration of post-ictal signs do not necessarily correlate with the severity of the seizure itself.

Nocturnal or sleep-onset events

Many seizures in dogs occur during rest or sleep, which means owners may first become aware of the condition when woken by unusual sounds or movements. Dogs may be found in a confused, disoriented state with evidence of urination or salivation, suggesting a seizure occurred during the night. The predominance of sleep-related events can make early seizures particularly difficult to identify and characterise.

Pre-ictal behavioural changes

Some dogs display recognisable behavioural shifts in the hours or minutes preceding a seizure, sometimes called an aura or prodrome. These might include unusual clinginess, restlessness, hiding, whining, or seeking out the owner. Not all dogs show consistent pre-ictal signs, but when present, they can become recognisable patterns over time.

Brief generalised episodes

The classic generalised tonic-clonic seizure involves loss of consciousness, falling to one side, rhythmic paddling of the limbs, jaw clenching, and often salivation, urination, or defecation. Initial events may be relatively brief — lasting 30 seconds to two minutes — and dogs often appear to recover fully between episodes. The dramatic nature of these events frequently prompts veterinary attention even when they are infrequent.

Later signals

Increasing seizure frequency

Over time, some dogs may experience a gradual increase in how often seizures occur, even with ongoing medication. What may begin as quarterly events can shift to monthly or more frequent episodes, though this trajectory is not inevitable and varies substantially between individuals. Changes in frequency often prompt reassessment of the management approach.

Cluster seizure patterns

Cluster seizures — multiple seizure events occurring within a 24-hour period — may develop as the condition progresses and represent a more complex management challenge. Dogs experiencing clusters may show prolonged post-ictal recovery and can be at greater risk of further events during the inter-ictal period. The emergence of clustering often influences decisions about medication adjustments and at-home management protocols.

Prolonged post-ictal effects

As the condition evolves, the recovery period following seizures may become more prolonged, with some dogs showing confusion, ataxia, or behavioural changes lasting 12 to 24 hours or longer. Persistent post-ictal neurological deficits, including temporary blindness or circling, can become more prominent. These extended recovery periods can significantly affect daily routine and quality of life.

Medication-related changes

Long-term anti-seizure medication use may produce observable side effects including increased appetite, weight gain, sedation, ataxia, or hepatic enzyme elevation detectable on blood work. Some dogs develop tolerance to medications over time, requiring dose adjustments or additional agents. Balancing seizure control against medication side effects becomes an ongoing consideration in long-term management.

Click to read about the biological mechanisms

How this is usually investigated

Investigation of seizures in dogs typically follows a systematic approach aimed at distinguishing between idiopathic epilepsy, structural brain disease, and reactive causes stemming from metabolic or toxic disturbances. The diagnostic pathway often narrows progressively, beginning with broad screening and advancing to more specialised imaging and testing based on initial findings, signalment, and seizure characteristics.

Comprehensive blood panel and urinalysis

Purpose: Baseline blood work including complete blood count, biochemistry panel, and urinalysis helps identify reactive causes of seizures such as hypoglycaemia, hepatic dysfunction, electrolyte imbalances, or renal compromise. These tests also establish pre-treatment baselines before initiating anti-seizure medications, many of which require ongoing blood monitoring.
Considerations: Results may be normal in dogs with idiopathic epilepsy, which itself provides useful diagnostic information. Bile acid testing may be recommended if hepatic encephalopathy is suspected, particularly in younger dogs. The timing of blood collection relative to seizure events can influence some parameters.

Advanced brain imaging (MRI)

Purpose: Magnetic resonance imaging provides detailed visualisation of brain structure, allowing identification of tumours, inflammatory lesions, vascular events, hydrocephalus, or developmental anomalies that may be causing structural epilepsy. MRI is generally considered the imaging modality of choice for investigating the epileptic brain, as it offers superior soft tissue contrast compared to CT.
Considerations: MRI requires general anaesthesia, which introduces its own considerations, particularly in a patient with a seizure history. Availability may be limited to referral centres, and cost can be a significant factor. Normal MRI findings support but do not definitively confirm a diagnosis of idiopathic epilepsy, as some microscopic pathology may not be visible on standard sequences.

Cerebrospinal fluid analysis

Purpose: Collection and analysis of cerebrospinal fluid (CSF) can reveal evidence of central nervous system inflammation, infection, or neoplastic processes. Cell counts, protein levels, cytology, and specific infectious disease testing (such as for Neospora, Toxoplasma, or tick-borne agents) help characterise inflammatory or infectious causes of seizures.
Considerations: CSF collection is typically performed under general anaesthesia, often in conjunction with MRI. The procedure carries a small risk of brain herniation in patients with significantly elevated intracranial pressure. Results may be normal in idiopathic epilepsy, and some inflammatory conditions can produce only subtle CSF changes.

Electroencephalography (EEG)

Purpose: EEG records the electrical activity of the brain and can identify abnormal patterns such as epileptiform discharges, focal abnormalities, or generalised spike-and-wave activity. While less routinely available in veterinary medicine than in human neurology, EEG can provide supportive evidence for epilepsy classification and help localise seizure foci.
Considerations: EEG interpretation in dogs can be challenging due to breed-related variation in normal patterns and the difficulty of obtaining recordings in unsedated patients. Availability is largely restricted to academic institutions and specialised referral centres. A normal inter-ictal EEG does not exclude epilepsy, as abnormal discharges may not be present between seizure events.

Toxicology screening

Purpose: When seizures present acutely, particularly in previously healthy dogs, toxin exposure may be a consideration. Screening for common neurotoxins including organophosphates, metaldehyde, permethrin (particularly in cats), and recreational drugs can identify reactive causes that may resolve with appropriate decontamination and supportive care.
Considerations: Specific toxicology panels vary between laboratories, and not all potential toxins can be readily tested for. A detailed history of possible environmental exposures is often more informative than blanket screening. The acute onset of seizures in a previously healthy dog, particularly with concurrent gastrointestinal signs or tremors, may raise toxin exposure as a consideration.

Options & trade-offs

Management of epilepsy in dogs typically involves pharmacological approaches aimed at reducing seizure frequency and severity, though complete elimination of seizures is not always achievable. The choice and combination of therapies often reflects individual factors including seizure type, frequency, severity, concurrent health conditions, and how each dog responds to specific medications over time.

Phenobarbital therapy

Phenobarbital is one of the most established anti-seizure medications in veterinary neurology, with decades of clinical use providing extensive data on its efficacy and safety profile. It works by enhancing GABAergic inhibition in the brain, raising the seizure threshold. Dosing is typically initiated at a standard level and adjusted based on serum drug level monitoring and clinical response. Many dogs achieve meaningful seizure reduction with phenobarbital as a sole agent.

Trade-offs: Common side effects include increased appetite, water consumption, urination, and initial sedation that often diminishes over weeks. Long-term use requires periodic monitoring of serum drug levels and liver enzyme values, as hepatotoxicity can develop in some individuals. The medication requires consistent twice-daily dosing, and abrupt discontinuation carries the risk of rebound seizures.

Potassium bromide therapy

Potassium bromide represents an alternative or adjunctive anti-seizure medication that works through a distinct mechanism — bromide ions compete with chloride at neuronal chloride channels, enhancing inhibitory neurotransmission. It is often used alongside phenobarbital when single-agent therapy provides insufficient seizure control, or as a primary agent when phenobarbital is poorly tolerated. Bromide has a long half-life, meaning steady-state concentrations may take several weeks to achieve.

Trade-offs: The extended time to reach therapeutic levels means clinical effect may not be apparent for four to six weeks after initiation. Gastrointestinal side effects including nausea and vomiting can occur, particularly during loading doses. Bromide is primarily excreted by the kidneys, and dietary salt content can significantly influence serum levels, requiring attention to dietary consistency.

Levetiracetam therapy

Levetiracetam is a newer anti-seizure medication with a distinct mechanism involving modulation of synaptic vesicle protein SV2A, which influences neurotransmitter release. It is generally well tolerated and has minimal hepatic metabolism, making it a useful option for dogs with pre-existing liver concerns. It may be used as a sole agent or in combination with other anti-seizure medications, and is sometimes administered as pulse therapy during cluster seizure events.

Trade-offs: The relatively short half-life in dogs typically necessitates three-times-daily dosing, which can affect owner compliance. The extended-release formulation offers twice-daily dosing but is more expensive. Some dogs may develop tolerance to levetiracetam over time, though this phenomenon is not universal and the clinical significance remains debated.

Combination medication protocols

When single-agent therapy fails to provide adequate seizure control, combinations of two or more anti-seizure medications with complementary mechanisms may be employed. Common combinations include phenobarbital with bromide, phenobarbital with levetiracetam, or triple therapy in refractory cases. The rationale for combination therapy is that targeting multiple mechanisms of seizure generation may provide additive or synergistic effects.

Trade-offs: Each additional medication introduces its own side effect profile and monitoring requirements, increasing the complexity and cost of management. Drug interactions may alter the metabolism and effective levels of individual agents, requiring careful dose adjustments. The incremental benefit of adding additional medications diminishes with each agent, and some dogs remain poorly controlled despite multi-drug regimens.

Dietary and lifestyle considerations

Emerging evidence suggests that dietary modification, including medium-chain triglyceride (MCT) supplementation and ketogenic-style diets, may provide adjunctive seizure reduction in some dogs through alternative brain energy metabolism. Environmental management — including identifying and minimising potential seizure triggers, maintaining consistent routines, and reducing stress — may also play a supportive role. These approaches are generally considered complementary to pharmacological management rather than replacements.

Trade-offs: The evidence base for dietary interventions in canine epilepsy is still developing, and responses appear highly variable between individuals. Dietary changes may cause gastrointestinal upset during transition periods. Identifying specific seizure triggers can be challenging, and maintaining highly controlled environments is not always practical for all households.

Common misconceptions

Misconception:

"A single seizure means a dog has epilepsy"

Reality:

A single seizure event does not constitute epilepsy. The definition of epilepsy requires recurrent, unprovoked seizures, and a single event may be reactive — triggered by a metabolic disturbance, toxin exposure, or transient physiological stress that does not recur. Veterinary professionals typically consider the frequency, pattern, and circumstances of seizure events before reaching a diagnosis of epilepsy. Investigation and monitoring following a first seizure helps establish whether the event represents an isolated occurrence or the beginning of a recurring condition.

Misconception:

"Dogs are in pain during a seizure"

Reality:

Although seizures are distressing to witness, the loss of consciousness that accompanies generalised tonic-clonic seizures means the dog is typically unaware of the event while it is occurring. The involuntary muscle contractions, vocalisation, and autonomic signs such as salivation and urination are neurological phenomena rather than indicators of pain perception. Post-ictal confusion and distress may be more reflective of disorientation than pain, though the experience likely varies between individuals and seizure types.

Misconception:

"Anti-seizure medication will completely stop all seizures"

Reality:

While medication can significantly reduce seizure frequency and severity in many dogs, complete seizure freedom is not always achievable — particularly in dogs with refractory epilepsy. The goal of medical management is often described as achieving the greatest possible reduction in seizure frequency while maintaining an acceptable quality of life, balancing seizure control against medication side effects. Approximately one-third of epileptic dogs may be considered drug-resistant, continuing to experience seizures despite appropriate multi-drug therapy, though individual responses vary considerably.

Understanding epilepsy as a condition involves recognising its inherently variable nature — patterns may shift over time, and what appears stable can change without obvious triggers. Maintaining detailed records of seizure events, including timing, duration, and any observable triggers or post-ictal patterns, can provide valuable context for ongoing discussions with veterinary professionals. The relationship between seizure management and quality of life encompasses not only seizure frequency but also medication side effects, behavioural changes, and the emotional impact on the household. Many dogs with epilepsy live full, active lives, though the journey of management often requires patience, flexibility, and ongoing communication with the veterinary team.

Last reviewed: 24 April 2026 · Dr Alastair Greenway MRCVS